About Supernus SUPN (adapted from Supernus SUPN prospectus): Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. They are developing product candidates in neurology and psychiatry to address large market opportunities in epilepsy and attention deficit hyperactivity disorder, or ADHD. Supernus intends to market their product candidates in the United States through their own focused sales force targeting specialty physicians, including neurologists and psychiatrists.
This description is adapted from Supernus SUPN prospectus. This description is not intended to be a recommendation to buy stock from this company. We do not claim that all of the statements above were researched and found to be true. We present them as a general description based on what the company has said about itself at the time that they submitted their prospectus for an IPO offering. To see the company's full description, view their prospectus..
IPO Boutique aggregates information on public companies and private companies, such as Supernus SUPN IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Our research is available by annual or monthly subscription or by one-week snapshots and single-company reports. Be informed.
Get our comprehensive reports. Monthly or Annual subscriptions—